Targeting proteins to cells expressing mannose receptors via expression in insect cells

• US 7,232,670 B2
• Filed: 09/28/2001
• Issued: 06/19/2007
• Est. Priority Date: 09/28/2001
• Status: Active Grant

• Current Assignee: St Jude Children's Research Hospital Incorporated (Abbott Laboratories)
• Original Assignee: St Jude Children's Research Hospital Incorporated (Abbott Laboratories)
• Inventors: Bonten, Erik Jacobus, D'Azzo, Alessandra
• Primary Examiner(s): Saidha; Tekchand
• Assistant Examiner(s): Fronda; Christian L.
• Application Number:
  US09/966,893
• Publication Number:
  US 20020077292A1
• Time in Patent Office: 2,090 Days
• Field of Search: 435/69.1, 435/183, 435/196, 435/213, 435/220, 514/2, 514/21, 530/350
• US Class Current: 435/183
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C12N 9/2402 hydrolysing O- and S- glycosyl compounds (3.2.1)
• CPC Class Codes: C12N 9/48 acting on peptide bonds (3.4)
• CPC Class Codes: C12Y 302/01018 Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
• CPC Class Codes: C12Y 304/16005 Carboxypeptidase C (3.4.16.5), i.e. carboxypeptidase Y

Abstract

The present invention is based on the discovery that proteins produced in insect cell cultures are glycosylated in a unique manner that causes them to be selectively imported by cells that express mannose receptors on their membranes, particularly macrophages. Proteins that are selectively imported into cells containing mannose receptors are provided, as well as pharmaceutical compositions containing such proteins and methods for producing such proteins. Application of the present invention to produce proteins useful for treating lysosomal storage disorders is also disclosed. Engineering of cells to express mannose receptors so that they will selectively import proteins produced in insect cells is also taught, as well as a protein targeting system using such cells and proteins. Finally, an improved elution buffer for the purification of proteins produced in insect cells from a Concanavalin A column is provided.

Claims

1. A pharmaceutical composition comprising a protein useful for treating a lysosomal storage disorder other than Fabry disease that is selectively imported into macrophages when administered to a subject and a pharmaceutically acceptable carrier, wherein said protein is produced in an insect cell culture and is selected from the group consisting of acid α

-1,4 glucosidase, acid α

-1,6 glucosidase, β

-galactosidase, β

-hexosaminidase A, GM₂ Activator Protein, β

-hexosaminidase A, β

-hexosaminidase B, glucocerebrosidase, β

-glucosidase, galactosylcerebrosidase, acid sphingomyelinase, acid ceramidase, acid lipase, α

-L-iduronidase, iduronate sulfatase, α

-N-acetylglucosaminidase, acetyl-CoA-glucosaminide acetyltransferase, N-acetylglucosamine-6-sulfatase, galactosamine-6-sulfatase, arvlsuylfatase B, β

-glucuronidase, arylsulfatase A, arylsulfatase C, α

-Neuraminidase, UDP GlcNAc;

lysosomal-enzyme N-acetylglucosamine-1-phosphotransferase, neuraminidase, α

-mannosidase, β

-mannosidase, α

-L-fucosidase, N-aspartyl-β

-glucosaminidase, protective proteinlcathepsin A (PPCA), α

-N-acetyl-galactosaminidase, cystine transport protein, sialic acid transport protein, palmitoyl-protein thioesterase, and Saposins A–

D.

2. The composition of claim 1 wherein said lysosomal storage disorder is Galactosialidosis.

3. The composition of claim 1 wherein said protein is protective protein/cathepsin A (PPCA).

4. The composition of claim 1 wherein said insect cell culture comprises cells derived from the species selected from the group consisting of Spodoptera frugiperda and Tricoplusia ni.

5. The composition of claim 4 wherein said cells are Spodoptera frugiperda Sf9 cells.

6. The composition of claim 1 wherein said protein is produced in the cell culture using a baculovirus expression system.

7. The composition of claim 1 wherein said lysosomal storage disorder and associated protein useful for treating said lysosomal storage disorder are selected from the group consisting of Pompe Disease and acid α

-1,4 glucosidase, Pompe Disease and acid α

-1,6 glucosidase, GM1 gangliosidosis and β

-galactosidase, Tay-Sachs disease and β

-hexosaminidase A, GM2 gangliosialidosis;

AB Variant and GM₂ Activator Protein, Sandhoff Disease and β

-hexosaminidase A, Sandhoff Disease and β

-hexosaminidase B, Gaucher Disease and glucocerebrosidase, Gaucher Disease and β

-glucodase, Krabbe Disease and galactosylcerebrosidase, Niemann-Pick Type A and acid sphingomyelinase, Niemann-Pick Type B and acid sphingomyelinase, Farber Disease and acid ceramidase, Wolman Disease and acid lipase, Cholesterol Ester Storage Disease and acid lipase, Hurler Syndrome and α

-L-iduronidase, Schie Syndrome and α

-L-iduronidase, Hurler-Schie and α

-L-iduronidase, Hunter Syndrome and iduronate 2-sulfate, Sanfilippo A and α

-N-acetylglucosaminidase, Sanfilippo B and α

-N-acetylglucosaminidase, Sanfilippo C and acetyl-CoA-glucosaminide acetyltransferase, Sanfilippo D and N-acetylglucosamine-6-sulfatase, Morquito A and N-acetylglucosamine-6-sulfate sulfatse, Morquito B and β

-galactosidase, Maroteaux-Lamy and arylsuylfatase B, Sly Syndrome and β

-glucuronidase, Metachromatic Leukodystrophy and arylsulfatase A, Multiple Sufatase Deficiency and arylsulfatase A, Multiple Sulfatase Deficiency and arylsulfatase B, Multiple Sulfatase Deficiency and arylsulfatase C, Sialidosis and α

-Neuraminidase, I-Cell Disease and UDP GicNAc;

lysosomal-enzyme N-acetylglucosamine-1-phosphotransferase, Pseudo-Hurler Polydistrophy and UDP GicNAc;

lysosomal-enzyme N-acetylglucosamine-1-phosphotransferase, Mucolipidosis IV and mucolipin-1, α

-Mannosidosis and α

-mannosidase, β

-Mannosidosis and β

-mannosidase, Fucosidosis and α

-L-fucosidase, Aspartylglucosaminuria and N-aspartyl-β

-glucosaminidase, Galactosialidosis and protective protein/cathepsin A, Galactosialidosis and neuraminidase, Galactosialidosis and β

-galactosidase, Schindler Disease and α

-N-acetyl-galactosaminidase, Cystinosis and cystine transport protein, Salla Disease and sialin, Infantile Sialie Acid Storage Disorder and sialin, Infantile Neuronal Ceroid Lipofuscinosis and palmitoyl-protein thioesterase, Prosaposin and Saposin A, Prosaposin and Saposin B, Prosaposin and Saposin C, and Prosaposin and Saposin D.

8. The composition of claim 7 wherein said lysosomal storage disorder is Sialidosis and said protein useful for treating said lysosomal storage disorder is a β

-Neuraminidase.